Last edition
News about "Fresenius Kabi "
Glenmark Launches Calcium Gluconate Injection in US
Glenmark launches Calcium Gluconate Injection USP in the US, offering a bioequivalent and therapeutically equivalent alternative to Fresenius Kabi’s reference drug.
Fresenius Kabi | 21/08/2026 | By News Bureau
Fresenius Kabi Recalls Tyenne Injection Vials Over Glass Particles
Fresenius Kabi recalls one lot of Tyenne (tocilizumab-aazg) 400 mg/20 mL injection vials nationwide after glass particles were found in the product.
Fresenius Kabi | 12/08/2026 | By News Bureau
Fresenius Wins US FDA and EMA Review Acceptance for Vedolizumab Biosimilar
Fresenius has secured US Food and Drug Administration (FDA) and European Medicines Agency (EMA) review acceptance for its vedolizumab biosimilar, targeting Ulcerative Colitis (UC) and Crohn's Disease (CD) in adults.
Fresenius Kabi | 03/08/2026 | By News Bureau | 513
Polpharma Biologics, Fresenius Kabi Partners to Commercialise A Proposed Vedolizumab Biosimilar
Polpharma Biologics, a European biotechnology company, has entered into a global licensing agreement with German multinational healthcare firm Fresenius Kabi for the commercialisation of PB016—a proposed biosimilar to vedolizumab.
Fresenius Kabi | 06/08/2025 | By Dineshwori | 372
Cellular Origins, Fresenius Kabi to Scale Up Automation of Cell and Gene Therapy Manufacturing
The agreement is designed with the goal of digitally and physically integrating Fresenius Kabi’s suite of cell therapy processing technologies within Cellular Origins’ CGT robotic manufacturing platform Constellation.
Fresenius Kabi | 17/10/2024 | By Aishwarya | 670
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy